Drugdocs | Erleada

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Erleada

Chemical Name	apalutamide
Dosage Form	Tablet (oral; 60 mg)
Drug Class	Inhibitors
System	Male reproductive
Company	Janssen Biotech
Approval Year	2018

Indication

Erleada is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer.
Erleada is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.

Last updated on 1/13/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Erleada (apalutamide) prescribing information.	2019	Janssen Biotech

Document Title	Year	Source
pan-Canadian oncology drug review final clinical guidance report: Apalutamide (Erleada) for metastatic castration sensitive prostate cancer.	2020	CADTH
Pharmacoeconomic report: Erleada (apalutamide).	2020	CADTH

Document Title	Year	Source
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: a systematic review and network meta-analysis.	2020	Urologic Oncology
Systemic management for nonmetastatic castration-resistant prostate cancer: A systematic review and network meta-analysis.	2020	American Journal of Clinical Oncology
A systematic review and network meta-analysis of novel androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer.	2020	Clinical Genitourinary Cancer
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.	2020	International Journal of Clinical Oncology
Management of non-metastatic castrate-resistant prostate cancer: A systematic review.	2018	Cancer Treatment Reviews